FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193561851> ?p ?o ?g. }

• W3193561851 abstract "SUMMARY Loss of homologous recombination repair (HRR) via germline and somatic BRCA1 or BRCA2 gene mutations and via BRCA1 promoter methylation has been associated with better response to platinum agents and PARP inhibitors, in both triple negative breast cancer (TNBC) and ovarian carcinoma (OvCa). A major conundrum arising from recent clinical studies is why cancers with BRCA1 promoter methylation ( BRCA1 meth) respond more poorly as compared to those bearing mutations in BRCA1 and BRCA2 ( BRCA mut), given the biologically equivalent HRR deficiency in both states. We dissected this problem through detailed genomic analyses of primary TNBC and OvCa cohorts, as well as experimentation with patient-derived xenograft (PDX) models and genetically engineered cell lines. Using the precise genomic scar of the tandem duplicator phenotype as a precise genomic indicator of BRCA1 deficiency, we found that, in all cohorts, BRCA1 mut and BRCA1 meth cancers share an equivalent degree of BRCA1-linked genomic rearrangements. Nonetheless, we consistently found that patients with BRCA mut cancers, but not those with BRCA1 meth cancers, had significantly better response outcomes when compared to those with BRCA proficient cancers. When fully promoter methylated BRCA1 PDX TNBCs were exposed to a single short course of platinum chemotherapy an unmethylated BRCA1 promoter allele emerged in resultant tumors associated with an increase in BRCA1 expression. A separate analysis of PDXs derived from treatment naïve TNBCs featured complete methylation of the BRCA1 promoter, whereas those derived from post-chemotherapy TNBCs invariably had only partial methylation. PDXs with partial methylation were significantly associated with lower response rates to in vivo platinum-based therapy compared to those with complete promoter methylation. Using single cell clonal expansions from a partially BRCA1 meth PDX, we confirmed that the reduced level of methylation was due to the demethylation of one of the BRCA1 promoter alleles and not to the outgrowth of a non-methylated clone. Clinically, analysis of primary OvCas confirmed that high levels of BRCA1 methylation were significantly associated with reduced BRCA1 gene expression whereas cancers with lower levels of BRCA1 methylation had expression levels approaching those found in BRCA1 proficient cancers. These data suggest that unlike BRCA mut cancers, where HRR deficiency is achieved via mutations that are genetically ‘fixed’, BRCA1 meth cancers are highly adaptive to genotoxin exposure and more likely to recover BRCA1 expression, which may explain their poorer therapeutic response. We further found that an increased immune transcriptional signal, especially an elevated M1 macrophage signature, is associated with enhanced response to platinum-based chemotherapy only in patients with BRCA proficient cancers, in both TNBC and OvCa cohorts underscoring the importance of characterizing molecular heterogeneity to enhance predictive precision in assigning response probabilities in TNBC and OvCa." @default.
• W3193561851 created "2021-08-30" @default.
• W3193561851 creator A5005961131 @default.
• W3193561851 creator A5011540763 @default.
• W3193561851 creator A5023917993 @default.
• W3193561851 creator A5037254064 @default.
• W3193561851 creator A5040467019 @default.
• W3193561851 creator A5041448171 @default.
• W3193561851 creator A5042689383 @default.
• W3193561851 creator A5044175725 @default.
• W3193561851 creator A5049538257 @default.
• W3193561851 creator A5053879641 @default.
• W3193561851 creator A5060021102 @default.
• W3193561851 creator A5061371711 @default.
• W3193561851 creator A5067107751 @default.
• W3193561851 creator A5078173518 @default.
• W3193561851 creator A5084420374 @default.
• W3193561851 date "2021-08-19" @default.
• W3193561851 modified "2023-09-24" @default.
• W3193561851 title "Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas" @default.
• W3193561851 cites W1781764024 @default.
• W3193561851 cites W1998914462 @default.
• W3193561851 cites W1999574084 @default.
• W3193561851 cites W2009164582 @default.
• W3193561851 cites W2019607817 @default.
• W3193561851 cites W2031757213 @default.
• W3193561851 cites W2039464502 @default.
• W3193561851 cites W2041440766 @default.
• W3193561851 cites W2046056066 @default.
• W3193561851 cites W2065817684 @default.
• W3193561851 cites W2074952360 @default.
• W3193561851 cites W2096283457 @default.
• W3193561851 cites W2096745115 @default.
• W3193561851 cites W2100419317 @default.
• W3193561851 cites W2101870168 @default.
• W3193561851 cites W2103441770 @default.
• W3193561851 cites W2105496345 @default.
• W3193561851 cites W2123696077 @default.
• W3193561851 cites W2130752875 @default.
• W3193561851 cites W2137538783 @default.
• W3193561851 cites W2146005104 @default.
• W3193561851 cites W2146512944 @default.
• W3193561851 cites W2149441684 @default.
• W3193561851 cites W2169145121 @default.
• W3193561851 cites W2171455999 @default.
• W3193561851 cites W2295085830 @default.
• W3193561851 cites W2430731787 @default.
• W3193561851 cites W2473878031 @default.
• W3193561851 cites W2557666746 @default.
• W3193561851 cites W2596164112 @default.
• W3193561851 cites W2606694952 @default.
• W3193561851 cites W2627028248 @default.
• W3193561851 cites W2734897937 @default.
• W3193561851 cites W2748606465 @default.
• W3193561851 cites W2765894258 @default.
• W3193561851 cites W2772484188 @default.
• W3193561851 cites W2779944044 @default.
• W3193561851 cites W2788106879 @default.
• W3193561851 cites W2788142646 @default.
• W3193561851 cites W2790556376 @default.
• W3193561851 cites W2796207838 @default.
• W3193561851 cites W2801496605 @default.
• W3193561851 cites W2801956643 @default.
• W3193561851 cites W2892812402 @default.
• W3193561851 cites W2904615282 @default.
• W3193561851 cites W2952760083 @default.
• W3193561851 cites W2976898289 @default.
• W3193561851 cites W2988901706 @default.
• W3193561851 cites W2998015544 @default.
• W3193561851 cites W3008697231 @default.
• W3193561851 cites W3015655761 @default.
• W3193561851 cites W3044764646 @default.
• W3193561851 cites W3083138967 @default.
• W3193561851 doi "https://doi.org/10.1101/2021.08.19.456799" @default.
• W3193561851 hasPublicationYear "2021" @default.
• W3193561851 type Work @default.
• W3193561851 sameAs 3193561851 @default.
• W3193561851 citedByCount "0" @default.
• W3193561851 crossrefType "posted-content" @default.
• W3193561851 hasAuthorship W3193561851A5005961131 @default.
• W3193561851 hasAuthorship W3193561851A5011540763 @default.
• W3193561851 hasAuthorship W3193561851A5023917993 @default.
• W3193561851 hasAuthorship W3193561851A5037254064 @default.
• W3193561851 hasAuthorship W3193561851A5040467019 @default.
• W3193561851 hasAuthorship W3193561851A5041448171 @default.
• W3193561851 hasAuthorship W3193561851A5042689383 @default.
• W3193561851 hasAuthorship W3193561851A5044175725 @default.
• W3193561851 hasAuthorship W3193561851A5049538257 @default.
• W3193561851 hasAuthorship W3193561851A5053879641 @default.
• W3193561851 hasAuthorship W3193561851A5060021102 @default.
• W3193561851 hasAuthorship W3193561851A5061371711 @default.
• W3193561851 hasAuthorship W3193561851A5067107751 @default.
• W3193561851 hasAuthorship W3193561851A5078173518 @default.
• W3193561851 hasAuthorship W3193561851A5084420374 @default.
• W3193561851 hasBestOaLocation W31935618511 @default.
• W3193561851 hasConcept C104317684 @default.
• W3193561851 hasConcept C121608353 @default.
• W3193561851 hasConcept C13514818 @default.
• W3193561851 hasConcept C143425029 @default.
• W3193561851 hasConcept C150194340 @default.

• next